HUTCHMED publishes 2025 annual report, posts $457 million net income attributable to shareholders

Reuters04-09 16:33

HUTCHMED publishes 2025 annual report, posts $457 million net income attributable to shareholders

HUTCHMED published its 2025 annual report, highlighting an inflection in China commercial momentum with 23% oncology product sales growth in H2 versus H1.
Takeda expanded FRUZAQLA rollout across 38 countries, driving 26% growth in in-market sales to USD 366.2 million.
ATTC platform moved into clinical stage with first patient dosed for HMPL-A251 in December 2025, followed by HMPL-A580 trial initiation in March 2026.
Savolitinib advanced toward broader global opportunity, with Swissmedic granting temporary authorization in February 2026 for use with TAGRISSO in 2L EGFR-mutant NSCLC with MET amplification or overexpression.
Late-stage pipeline progressed in China, with NMPA accepting an NDA for fanregratinib in 2L intrahepatic cholangiocarcinoma in December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260409-12099368), on April 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626902471?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626902471","market":"nz","top_or_hot":-1,"title":"HUTCHMED publishes 2025 annual report, posts $457 million net income attributable to shareholders","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED publishes 2025 annual report, posts $457 million net income attributable to shareholders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          HUTCHMED published its 2025 annual report, highlighting an inflection in China commercial momentum with 23% oncology product sales growth in H2 versus H1.\n        </li>\n<li>\n          Takeda expanded FRUZAQLA rollout across 38 countries, driving 26% growth in in-market sales to USD 366.2 million.\n        </li>\n<li>\n          ATTC platform moved into clinical stage with first patient dosed for HMPL-A251 in December 2025, followed by HMPL-A580 trial initiation in March 2026.\n        </li>\n<li>\n          Savolitinib advanced toward broader global opportunity, with Swissmedic granting temporary authorization in February 2026 for use with TAGRISSO in 2L EGFR-mutant NSCLC with MET amplification or overexpression.\n        </li>\n<li>\n          Late-stage pipeline progressed in China, with NMPA accepting an NDA for fanregratinib in 2L intrahepatic cholangiocarcinoma in December 2025.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260409-12099368), on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED publishes 2025 annual report, posts $457 million net income attributable to shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED publishes 2025 annual report, posts $457 million net income attributable to shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-09 16:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HUTCHMED publishes 2025 annual report, posts $457 million net income attributable to shareholders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          HUTCHMED published its 2025 annual report, highlighting an inflection in China commercial momentum with 23% oncology product sales growth in H2 versus H1.\n        </li>\n<li>\n          Takeda expanded FRUZAQLA rollout across 38 countries, driving 26% growth in in-market sales to USD 366.2 million.\n        </li>\n<li>\n          ATTC platform moved into clinical stage with first patient dosed for HMPL-A251 in December 2025, followed by HMPL-A580 trial initiation in March 2026.\n        </li>\n<li>\n          Savolitinib advanced toward broader global opportunity, with Swissmedic granting temporary authorization in February 2026 for use with TAGRISSO in 2L EGFR-mutant NSCLC with MET amplification or overexpression.\n        </li>\n<li>\n          Late-stage pipeline progressed in China, with NMPA accepting an NDA for fanregratinib in 2L intrahepatic cholangiocarcinoma in December 2025.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260409-12099368), on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL4yzgx6:1","article_id":"2626902471","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626902471","pubTimestamp":1775723635,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HUTCHMED published its 2025 annual report, highlighting an inflection in China commercial momentum with 23% oncology product sales growth in H2 versus H1.Takeda expanded FRUZAQLA rollout across 38 countries, driving 26% growth in in-market sales to USD 366.2 million.ATTC platform moved into clinical stage with first patient dosed for HMPL-A251 in December 2025, followed by HMPL-A580 trial initiation in March 2026.Savolitinib advanced toward broader global opportunity, with Swissmedic granting temporary authorization in February 2026 for use with TAGRISSO in 2L EGFR-mutant NSCLC with MET amplification or overexpression.Late-stage pipeline progressed in China, with NMPA accepting an NDA for fanregratinib in 2L intrahepatic cholangiocarcinoma in December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药","BK1587":"次新股","BK1191":"制药","BK1588":"回港中概股"},"translate_title":"和黄医药发布2025年年报，股东应占净利润4.57亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":0.9},"content_text":"HUTCHMED publishes 2025 annual report, posts $457 million net income attributable to shareholders\n    \n\n\n          HUTCHMED published its 2025 annual report, highlighting an inflection in China commercial momentum with 23% oncology product sales growth in H2 versus H1.\n        \n\n          Takeda expanded FRUZAQLA rollout across 38 countries, driving 26% growth in in-market sales to USD 366.2 million.\n        \n\n          ATTC platform moved into clinical stage with first patient dosed for HMPL-A251 in December 2025, followed by HMPL-A580 trial initiation in March 2026.\n        \n\n          Savolitinib advanced toward broader global opportunity, with Swissmedic granting temporary authorization in February 2026 for use with TAGRISSO in 2L EGFR-mutant NSCLC with MET amplification or overexpression.\n        \n\n          Late-stage pipeline progressed in China, with NMPA accepting an NDA for fanregratinib in 2L intrahepatic cholangiocarcinoma in December 2025.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260409-12099368), on April 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626902471","isCrawlerRequest":true}